Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
26 studies found for:    Avanir
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed PRISM Registry: Pseudobulbar Affect Registry Series
Conditions: Alzheimer's Disease;   Amyotrophic Lateral Sclerosis (ALS);   Multiple Sclerosis (MS);   Parkinson's Disease;   Stroke;   Traumatic Brain Injury
Intervention:
2 Completed A Phase 1 Study Comparing AVP-786 With AVP-923
Condition: Healthy Volunteer
Interventions: Drug: AVP-786;   Drug: AVP-923
3 Completed
Has Results
Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
Condition: Pseudobulbar Affect (PBA)
Interventions: Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;   Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;   Drug: Placebo
4 Recruiting Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition
Condition: Disinhibition Syndrome
Interventions: Drug: AVP-786;   Drug: Placebo
5 Recruiting Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Condition: Agitation in Patients With Dementia of the Alzheimer's Type
Intervention: Drug: AVP-786
6 Recruiting Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Condition: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: Drug: AVP-786;   Drug: Placebo
7 Recruiting Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Condition: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: Drug: AVP-786;   Drug: Placebo
8 Not yet recruiting Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Traumatic Brain Injury
Condition: Neurobehavioral Disinhibition
Interventions: Drug: AVP-786;   Drug: Placebo
9 Terminated Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)
Condition: Pseudobulbar Affect (Involuntary Laughing and/or Crying)
Intervention: Drug: NUEDEXTA®
10 Active, not recruiting Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
Condition: Schizophrenia
Interventions: Drug: AVP-786;   Drug: Placebo
11 Completed Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts
Condition: Healthy
Interventions: Drug: AVP-923;   Drug: AVP-786;   Drug: Itraconazole
12 Completed A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers
Condition: Healthy
Interventions: Drug: AVP-786;   Drug: AVP-923
13 Completed A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects
Condition: Drug-drug Interaction
Interventions: Drug: AVP-786;   Drug: Paroxetine;   Drug: Duloxetine
14 Completed Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Condition: Depressive Disorder, Treatment-Resistant
Interventions: Drug: AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination);   Drug: Placebo
15 Completed
Has Results
Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
Conditions: Pseudobulbar Affect (PBA);   Stroke;   Dementia;   Traumatic Brain Injury (TBI)
Intervention: Drug: Nuedexta (DM 20 mg/Q 10 mg)
16 Completed Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers
Condition: Healthy
Interventions: Drug: AVP-786 Dose 1;   Drug: AVP-786 Dose 2;   Drug: AVP-786 Dose 1/Q Dose 1;   Drug: AVP-786 Dose 1/Q Dose 2;   Drug: AVP-786 Dose 2/Q Dose 2;   Drug: AVP-923
17 Completed Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
Conditions: Dyskinesia;   Parkinson's Disease
Interventions: Drug: AVP-923-45;   Drug: Placebo
18 Completed
Has Results
Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura
Conditions: Migraine;   Headaches
Interventions: Drug: 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally;   Drug: OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet
19 Completed Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Conditions: Agitation;   Alzheimer's Disease
Interventions: Drug: AVP-923 (dextromethorphan/quinidine);   Drug: Placebo
20 Completed Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Conditions: Central Neuropathic Pain;   Multiple Sclerosis
Intervention: Drug: AVP-923

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.